Evidence map›Paper›PMID 41972846›Full record

ArticleInternational journal of cancer2026

Hypoxia Induces a Mitotic Survival Advantage After Radiotherapy in Head and Neck Cancer Cells.

Marilyn Wegge, Rüveyda Dok, Ludwig J Dubois, Sandra Nuyts

Abstract read
In one paragraph

Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Marilyn WeggeLaboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven, University of Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0002-6053-5993
Rüveyda DokLaboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven, University of Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0002-5456-814X
Ludwig J DuboisThe M-Lab, Department of Precision Medicine, GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands.
Sandra NuytsLaboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven, University of Leuven, Leuven, Belgium.

Funding

Fonds Wetenschappelijk Onderzoek 18B4122NKom op tegen Kanker Emmanuel van der Schueren fellowship for pre-doctoral studentsStichting Tegen Kanker C/2020/1463
6 · The paper itself

Abstract

Hypoxia is an important cause of radiotherapy resistance in head and neck cancers. Cancer cells adapt to hypoxic conditions through various molecular alterations, leading to treatment resistance and tumor progression. A deeper understanding of these hypoxia-induced molecular alterations is essential for future development of effective hypoxia targeting and radiosensitizing therapies. In this study, we tracked (post-)hypoxic cells at single-cell level in HPV-negative and HPV-positive HNSCC models using a hypoxia fate mapping system. We found that (post-)hypoxic cells drive regrowth after radiotherapy in 3D conditions and showed an increased resistance to radiation. Transcriptomic analysis showed that post-hypoxic cells are characterized by a gene expression signature mainly defined by checkpoint regulation. Consistent with these findings, radiotherapy resistant post-hypoxic cells showed a reduced number of radiotherapy-induced micronuclei and mitotic spindle aberrations, indicating a mitotic survival advantage. Inhibition of mitotic checkpoint proteins ATR and CHK1/2 increased the radiosensitivity of post-hypoxic cells. In conclusion, our findings indicate that radiotherapy resistance in HNSCC cells is associated with mitotic survival advantage of post-hypoxic cells, independent of HPV-status.

Indexed as

Head and Neck NeoplasmsMitosisRadiation ToleranceSquamous Cell Carcinoma of Head and NeckCell HypoxiaCell Line, TumorCell SurvivalHumanshead and neck cancerhuman papillomavirushypoxiamitosisradiotherapy

Identifiers

PMID41972846
PMCPMC13284633

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.